MedTrace Logo

Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis

NCT01084538 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 181

Last updated 2011-09-21

Study results available
· View outcomes & findings →

Summary

This is the post-marketing study conducted in two countries: Croatia and Serbia. In both countries Zemplar (paricalcitol) is the first injectable form of any Vitamin D Receptor (VDR) activator available for chronic kidney disease patients on hemodialysis. The evaluation of outcomes of VDR activator treatments in clinical practice is a major challenge in the management of this patient population. The aim of this post-marketing observational study is to obtain further data on the outcomes of Zemplar Injection administration during routine clinical use.

Conditions

  • Parathyroid Hormone

Interventions

DRUG

Zemplar iv (paricalcitol iv)

Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.

Sponsors & Collaborators

Principal Investigators

  • Marta Gunjaca, MD · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Croatia
  • Serbia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01084538 on ClinicalTrials.gov